Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital reaffirmed its "Buy" rating on Compass Therapeutics and set a $30 price target, which would imply about a 498% upside from the stock's previous close.
• Analyst views vary: one analyst has a Strong Buy, eleven have Buy and one has Sell, giving a consensus rating of "Moderate Buy" with a consensus price target of $13.11.
• The stock opened at $5.01 (50‑day SMA $5.55, 200‑day SMA $5.30) with a market cap of ~$902.8M; Compass reported a quarterly EPS of ($0.09), beating estimates by $0.01, and about 68.43% of shares are institutionally owned.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating restated by equities researchers at D. Boral Capital in a report issued on Monday,Benzinga reports. They currently have a $30.00 target price on the stock. D. Boral Capital's price target would suggest a potential upside of 498.44% from the stock's previous close.

Several other research firms have also recently weighed in on CMPX. Craig Hallum assumed coverage on Compass Therapeutics in a research note on Friday, February 13th. They issued a "buy" rating and a $15.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Compass Therapeutics in a report on Thursday, March 12th. Guggenheim reissued a "buy" rating and issued a $12.00 target price on shares of Compass Therapeutics in a research report on Tuesday, March 24th. Canaccord Genuity Group set a $13.00 price target on shares of Compass Therapeutics in a research note on Wednesday, February 4th. Finally, Raymond James Financial reissued an "outperform" rating on shares of Compass Therapeutics in a report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $13.11.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock opened at $5.01 on Monday. The company has a 50-day simple moving average of $5.55 and a two-hundred day simple moving average of $5.30. The stock has a market capitalization of $902.79 million, a PE ratio of -11.66 and a beta of 1.49. Compass Therapeutics has a 52-week low of $1.66 and a 52-week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. As a group, equities research analysts forecast that Compass Therapeutics will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of large investors have recently made changes to their positions in the company. Pictet Asset Management Holding SA purchased a new position in shares of Compass Therapeutics in the first quarter worth approximately $76,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Compass Therapeutics in the 4th quarter worth $132,000. Seven Fleet Capital Management LP purchased a new stake in shares of Compass Therapeutics in the 4th quarter worth $3,054,000. Invesco Ltd. raised its holdings in Compass Therapeutics by 5.3% in the 4th quarter. Invesco Ltd. now owns 63,901 shares of the company's stock worth $343,000 after purchasing an additional 3,245 shares during the period. Finally, XTX Topco Ltd lifted its position in Compass Therapeutics by 582.2% during the fourth quarter. XTX Topco Ltd now owns 115,634 shares of the company's stock valued at $621,000 after purchasing an additional 98,684 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.